Twice over the past two years, Eisai won FDA approval for new drugs and the endorsements triggered an important five-year period in which generic competition could be kept at bay.
But Eisai quickly ran into delays launching its drugs. Both of its medicines – the Belviq diet pill and the Fycompa epilepsy treatment – are controlled substances. And this meant these could not be marketed until the U.S. Drug Enforcement Agency placed them on lists of drugs for which distribution is restricted.
Help employers find you! Check out all the jobs and post your resume.
